TrialPediatric nephrology (Berlin, Germany)2023

ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.

Gema Ariceta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.